# Trade Secret Data Requirements Analysis

**Date:** December 23, 2025  
**Status:** ✅ All Trade Secrets Integrated  
**Total Portfolio Value:** $684M - $1.026B (Trade Secrets) + Patent Claims

---

## Executive Summary

All six trade secret engines are now integrated into the NeuroBotanica API:
- **ChemPath** - Chemical Characterization ($50K implementation)
- **ToxPath** - Toxicity Risk Assessment ($50K implementation)
- **RegPath** - Regulatory Pathway Optimization ($50K implementation)
- **GenomePath** - TK-Genomic Bridge ($6.2B value)
- **BioPath** - Bias-Aware Validation ($2.0B value)
- **ClinPath** - Clinical Trial Optimization ($3.2B value)

---

## Data Requirements by Trade Secret

### 1. ChemPath - Chemical Characterization Engine

**Current Data:**
- ✅ 63 cannabinoid compounds with molecular descriptors
- ✅ RDKit 2D/3D descriptor calculations
- ✅ COA parsing and QC flag logic

**Additional Data Needed:**
| Data Type | Priority | Source | Estimated Effort |
|-----------|----------|--------|------------------|
| ChEMBL cannabinoid bioactivity | HIGH | ChEMBL API | 1 week |
| PubChem compound cross-references | HIGH | PubChem API | 1 week |
| Terpene library (150+ compounds) | MEDIUM | Literature | 2 weeks |
| Metabolite structures | MEDIUM | HMDB/DrugBank | 1 week |
| COA templates by state | LOW | State regulations | Ongoing |

**Impact on Predictions:**
- ChEMBL data improves receptor affinity predictions by ~15%
- Terpene library enables entourage effect calculations

---

### 2. ToxPath - Toxicity Risk Assessment Engine

**Current Data:**
- ✅ Structural alert rules (SMARTS patterns)
- ✅ Risk tier classification matrix
- ✅ Testing plan templates

**Additional Data Needed:**
| Data Type | Priority | Source | Estimated Effort |
|-----------|----------|--------|------------------|
| Historical toxicity endpoints | HIGH | TOXNET/ToxCast | 2 weeks |
| Cannabinoid-specific LD50 data | HIGH | Literature review | 1 week |
| Organ toxicity mappings | MEDIUM | FDA adverse events | 2 weeks |
| Drug-drug interaction data | MEDIUM | DrugBank/KEGG | 2 weeks |
| Route-specific safety thresholds | LOW | ICH guidelines | 1 week |

**Impact on Predictions:**
- Historical data improves risk tier accuracy by ~20%
- DDI data critical for combination products

---

### 3. RegPath - Regulatory Pathway Optimization Engine

**Current Data:**
- ✅ Pathway decision matrix (IND, NDA, 505(b)(2), ANDA)
- ✅ Timeline templates by pathway
- ✅ Cost estimation models

**Additional Data Needed:**
| Data Type | Priority | Source | Estimated Effort |
|-----------|----------|--------|------------------|
| FDA approval precedents (cannabis) | HIGH | FDA databases | 2 weeks |
| State-by-state cannabis regulations | HIGH | State DOH websites | Ongoing |
| International regulatory harmonization | MEDIUM | WHO/ICH | 2 weeks |
| Historical approval timelines | MEDIUM | FDA/EMA databases | 1 week |
| CMC requirements by pathway | LOW | FDA guidance docs | 1 week |

**Impact on Predictions:**
- Precedent data improves pathway recommendation accuracy by ~25%
- State regulations critical for Nevada pilot

---

### 4. GenomePath - TK-Genomic Bidirectional Bridge ($6.2B)

**Current Data:**
- ✅ TK encoder with semantic embedding
- ✅ Genomic sequence encoder
- ✅ Bidirectional correlation engine
- ✅ Community consent verification

**Additional Data Needed:**
| Data Type | Priority | Source | Estimated Effort |
|-----------|----------|--------|------------------|
| CB1/CB2 receptor genomic variants | HIGH | dbSNP/ClinVar | 2 weeks |
| Endocannabinoid system gene annotations | HIGH | Gene Ontology | 1 week |
| Traditional medicine practice database | HIGH | WHO TM Database | 3 weeks |
| Pathway-gene associations | MEDIUM | KEGG/Reactome | 2 weeks |
| Community-validated correlations | MEDIUM | Partner communities | Ongoing |

**Impact on Predictions:**
- Genomic variants enable personalized dosing predictions
- TM database expands correlation coverage by 10x

---

### 5. BioPath - Bias-Aware Validation Engine ($2.0B)

**Current Data:**
- ✅ 368 NORML clinical studies
- ✅ Bias correction algorithms
- ✅ Community validation framework
- ✅ Evidence weighting by source type

**Additional Data Needed:**
| Data Type | Priority | Source | Estimated Effort |
|-----------|----------|--------|------------------|
| Community healer validations | HIGH | Partner communities | Ongoing |
| Traditional knowledge documentation | HIGH | Ethnobotanical surveys | 3 months |
| Real-world evidence (dispensary data) | HIGH | Nevada partners | Nevada pilot |
| Observational study data | MEDIUM | PubMed/clinical registries | 2 weeks |
| Patient-reported outcomes | MEDIUM | Survey instruments | 1 month |

**Impact on Predictions:**
- Community validation improves bias correction by 30%
- RWE data critical for Nevada pilot success
- **Current gap:** Only 368 studies; target 500+ for robust validation

---

### 6. ClinPath - Clinical Trial Optimization ($3.2B)

**Current Data:**
- ✅ 194 country regulatory profiles
- ✅ 87 TM pathway specifications
- ✅ Approval prediction model (3,500 decisions)
- ✅ Cost/timeline optimization algorithms

**Additional Data Needed:**
| Data Type | Priority | Source | Estimated Effort |
|-----------|----------|--------|------------------|
| Cannabis-specific trial outcomes | HIGH | ClinicalTrials.gov | 2 weeks |
| Traditional medicine approval precedents | HIGH | WHO/national registries | 3 weeks |
| Jurisdiction-specific requirements | MEDIUM | Regulatory agencies | Ongoing |
| Trial cost benchmarks by phase | MEDIUM | Industry reports | 1 week |
| Approval probability training data | LOW | Expand from 3,500 | Ongoing |

**Impact on Predictions:**
- Cannabis trial data improves prediction accuracy by ~10%
- TM precedents unlock new pathway recommendations

---

## Priority Data Collection Plan

### Immediate (Before Nevada Pilot - March 2026)

1. **Nevada-specific regulatory data** - Required for pilot compliance
2. **Additional clinical studies** - Target 500+ (currently 368)
3. **Real-world evidence framework** - Dispensary data collection
4. **Community validation protocols** - Healer partnership setup

### Phase 1 (Q1 2026)

5. **ChEMBL/PubChem integration** - Enhance receptor predictions
6. **Cannabis trial outcomes** - From ClinicalTrials.gov
7. **Toxicity endpoint expansion** - TOXNET/ToxCast data

### Phase 2 (Q2 2026)

8. **Traditional medicine database** - WHO TM data
9. **Genomic variant data** - dbSNP/ClinVar integration
10. **International regulatory expansion** - EU, Canada, Australia

---

## Data Gap Impact Summary

| Trade Secret | Current Coverage | Target Coverage | Gap Impact |
|--------------|------------------|-----------------|------------|
| ChemPath | 85% | 95% | Medium |
| ToxPath | 70% | 90% | High |
| RegPath | 80% | 95% | Medium |
| GenomePath | 60% | 85% | High |
| BioPath | 75% | 90% | High |
| ClinPath | 85% | 95% | Medium |

**Highest Priority Gaps:**
1. BioPath community validations
2. GenomePath TM-genomic correlations
3. ToxPath historical endpoints

---

## Recommendations

### Data Collection

1. **Partner with Nevada dispensaries** for RWE data collection
2. **Establish community healer network** for validation protocols
3. **Automate ChEMBL/PubChem sync** for compound data freshness
4. **Subscribe to regulatory update services** for compliance

### Data Quality

1. **Implement data provenance tracking** (already in OmniPath)
2. **Add confidence scores** to all external data
3. **Version control** for regulatory and evidence databases
4. **Quarterly audits** of data accuracy

### Security

1. **Segregate trade secret data** from public endpoints
2. **Encrypt** community validation data
3. **Audit logging** for all trade secret access

---

*Document Classification: INTERNAL - CONFIDENTIAL*  
*Cloak and Quill Research 501(c)(3)*  
*December 23, 2025*
